Why Asthma Clinical Trials Matter in the UK Right Now
The UK has long been a hub for respiratory research. Institutions like the National Heart and Lung Institute at Imperial College London, the Royal Brompton Hospital, and the University of Manchester run some of the most influential asthma studies in the world. The NIHR (National Institute for Health and Care Research) has also partnered with pharmaceutical companies such as AstraZeneca on trials investigating biologic treatments targeting specific inflammatory pathways like IL-13 and TSLP.
A key development is the integration of the Be Part of Research service into the NHS app. This means patients can now be matched with suitable asthma trials based on their health records, removing much of the guesswork from the search process. The platform also maintains a volunteer registry for those interested in future studies.
Despite this infrastructure, a persistent challenge affects the quality of research: certain groups remain underrepresented. A recent analysis by the British Youth Health Association noted that 18- to 24-year-olds make up roughly 8% of the UK population but account for only 4.4% of trial participants. This gap means treatments tested primarily on older adults may not work the same way in younger bodies. The same underrepresentation affects women and ethnic minority groups in many respiratory studies.
Types of Asthma Trials Recruiting in the UK
Asthma trials fall into several broad categories, and knowing the differences helps narrow your search.
Biologic therapy trials dominate the current landscape. These investigate monoclonal antibodies that target specific immune pathways. Benralizumab, which targets eosinophils, was studied in the ABRA trial at Oxford University Hospitals and showed that a single injection during an acute exacerbation reduced treatment failure rates significantly compared to standard prednisolone. Tezepelumab, blocking TSLP, went through the DESTINATION phase 3 trial with UK sites including the Royal Brompton. Dupilumab and mepolizumab continue to be studied in real-world settings through the UK Severe Asthma Registry.
Inhaled corticosteroid comparisons test new formulations against existing products. For instance, beclometasone inhaler trials evaluate whether generic versions perform as effectively as branded originals in maintaining lung function over time.
Non-pharmacological interventions also feature in UK research. A randomised controlled trial coordinated through the University of Southampton examined physiotherapy-based breathing retraining for asthma, finding measurable improvements in quality-of-life scores among participants.
Diagnostic and monitoring studies explore tools like exhaled breath volatile analysis, developed at the Manchester NIHR Biomedical Research Centre, which could one day replace more invasive tests for asthma diagnosis and monitoring.
Here is a comparison of common trial types you might encounter when searching UK registries:
| Trial Category | Example Intervention | Typical Phase | Duration | Potential Benefit | Key Consideration |
|---|
| Biologic therapy | Benralizumab injection | Phase 2-3 | 24-52 weeks | Reduced exacerbations | Requires regular hospital visits |
| Inhaled therapy comparison | Beclometasone HFA inhaler | Phase 3 | 8-12 weeks | Access to new formulations | May involve placebo arm |
| Breathing retraining | Physiotherapy programme | Phase 3-4 | 12-16 weeks | Non-drug approach | Time commitment for sessions |
| Digital monitoring | Remote lung function tracking | Observational | 6-12 months | Convenient participation | No direct treatment benefit |
| Early-phase biologic | Novel bispecific antibody | Phase 1-2 | 12-24 weeks | Access to cutting-edge therapy | Higher uncertainty about outcomes |
What Participation Actually Looks Like
Tom, a 42-year-old teacher from Manchester, had been on high-dose ICS-LABA combinations for six years with persistent symptoms. His consultant mentioned a biologic trial at the local NIHR centre. After screening that included blood eosinophil counts, lung function tests, and an asthma control questionnaire, he was enrolled in a 48-week study. "The monitoring was intensive at first—weekly visits for the first month—but then settled into monthly check-ins," he explained. His exacerbations dropped from four per year to one.
The screening process itself is methodical. Researchers check that your asthma diagnosis is confirmed, your current treatment regimen has been stable for a defined period, and your lung function falls within the trial's specified range. Blood tests often look for biomarkers like eosinophil levels that indicate whether a particular biologic might work for you. Exclusion criteria commonly rule out people with certain other lung conditions, pregnancy or planned pregnancy, and recent use of specific medications that could interfere with results.
Most trials provide study medication at no cost, and travel expenses are usually reimbursed. The intensity of monitoring means participants often receive more frequent health checks than they would through routine NHS care.
How to Find and Join a Trial
The most direct route is through your respiratory consultant or GP. Specialists at major centres like the Royal Brompton in London, the University Hospital of South Manchester, or Southampton General Hospital are often investigators on multiple studies and can discuss whether any active trials match your profile.
For self-directed searching, the Be Part of Research website aggregates trials from UK registries and allows filtering by condition, location, and phase. The WHO International Clinical Trials Registry Platform provides a broader global view, though UK-specific filters help narrow results. Asthma + Lung UK, the charity formed from the merger of Asthma UK and the British Lung Foundation, also provides signposting information on its website.
Before enrolling, you will go through an informed consent process where the study team explains the purpose, procedures, risks, and your right to withdraw at any point. An ethics committee must have approved the trial, and this approval is documented in the study records.
Questions worth asking the research team include what the time commitment involves, whether the trial includes a placebo group, what happens after the study ends, and how results will be shared with participants.
Regional Resources and Practical Considerations
Research activity concentrates in certain UK regions. London hosts multiple sites through Imperial College and the Royal Brompton. Manchester has a strong programme through its NIHR Biomedical Research Centre. Southampton coordinates several national respiratory trials. Scotland and Wales have their own research networks, and the devolved health systems sometimes run separate recruitment streams.
Travel can be a practical barrier. Some trials now incorporate remote monitoring elements, using apps and home spirometry devices to reduce the number of hospital visits. This shift towards decentralised trial designs has accelerated and may make participation feasible even if you live some distance from a major centre.
People with mild or well-controlled asthma sometimes assume trials are only for severe cases, but this is not always true. Phase 1 studies testing safety often recruit healthy volunteers or those with milder disease. Observational studies need participants across the severity spectrum to understand how asthma behaves in different populations.
The UK Severe Asthma Registry, which collects real-world data on biologic treatments, has shown that many patients who would not have qualified for the tightly controlled randomised trials still benefit meaningfully from these therapies. This finding underscores why broadening participation matters—real-world evidence depends on real-world participants.
If you have been on the same inhaler regimen for years and still wake up at night with symptoms, or if you rely on oral steroids more than twice a year, a conversation with your healthcare team about research options may be worthwhile. The landscape of asthma treatment is shifting faster than it has in decades, and the UK's research infrastructure offers a structured, well-regulated path to being part of that change.
研究の知恵